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Abstract
The intramembrane-cleaving protease c-secretase catalyzes the last step in the generation of toxic amyloid-b (Ab) peptides
and is a principal therapeutic target in Alzheimer’s disease. Both preclinical and clinical studies have demonstrated that
inhibition of c-secretase is associated with prohibitive side effects due to suppression of Notch processing and signaling.
Potentially safer are c-secretase modulators (GSMs), which are small molecules that selectively lower generation of the
highly amyloidogenic Ab42 peptides but spare Notch processing. GSMs with nanomolar potency and favorable
pharmacological properties have been described, but the molecular mechanism of GSMs remains uncertain and both the
substrate amyloid precursor protein (APP) and subunits of the c-secretase complex have been proposed as the molecular
target of GSMs. We have generated a potent photo-probe based on an acidic GSM that lowers Ab42 generation with an IC50
of 290 nM in cellular assays. By combining in vivo photo-crosslinking with affinity purification, we demonstrated that this
probe binds the N-terminal fragment of presenilin (PSEN), the catalytic subunit of the c-secretase complex, in living cells.
Labeling was not observed for APP or any of the other c-secretase subunits. Binding was readily competed by structurally
divergent acidic and non-acidic GSMs suggesting a shared mode of action. These findings indicate that potent acidic GSMs
target presenilin to modulate the enzymatic activity of the c-secretase complex.
Citation: Jumpertz T, Rennhack A, Ness J, Baches S, Pietrzik CU, et al. (2012) Presenilin Is the Molecular Target of Acidic c-Secretase Modulators in Living
Cells. PLoS ONE 7(1): e30484. doi:10.1371/journal.pone.0030484
Editor: Thomas Langmann, University of Regensburg, Germany
Received November 7, 2011; Accepted December 16, 2011; Published January 6, 2012
Copyright:  2012 Jumpertz et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was supported by the Competence Network Degenerative Dementias of the Federal Ministry of Education (www.bmbf.de/en; grant
numbers 01 GI 1004D, 01 GI 1004C, 01 GI 1004B to CUP, BB, and SW). The funders had no role in study design, data collection and analysis, decision to publish, or
preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: bruno.bulic@caesar.de (BB); sweggen@uni-duesseldorf.de (SW)
. These authors contributed equally to this work.
Introduction
Alzheimer’s disease (AD) is the most common age-related
neurodegenerative disease with an estimated 5.4 million patients in
the USA [1]. It is believed that progressive neurodegeneration and
cognitive decline in AD are triggered by oligomerization and
accumulation of toxic amyloid-b (Ab) peptides in the brain. The
amyloid hypothesis is strongly supported by the analysis of early-
onset familial forms of AD (FAD), which has demonstrated that
modest overproduction of the oligomerization-prone Ab42
peptides in the brain is sufficient to cause AD with complete
penetrance [2].
The intramembrane-cleaving protease c-secretase is responsible
for the last step in the proteolytic release of Ab42 peptides from the
amyloid precursor protein (APP), and is a principal therapeutic
target in AD [3]. c-Secretase is a multi-subunit aspartyl protease
with the presenilin (PSEN) proteins, either PSEN1 or PSEN2, as
its catalytic core. PSEN proteins encompass nine transmembrane
domains (TMDs) and are endoproteolytically cleaved during
assembly of the c-secretase complex into N- and C-terminal
fragments that remain non-covalently associated. The PSEN
fragments are incorporated together with three accessory proteins,
nicastrin, anterior pharynx defective-1 (APH-1) and presenilin
enhancer-2 (PEN-2), into high molecular weight complexes that
display proteolytic activity [3]. Two critical aspartate residues in
TMD6 and TMD7 of PSEN form the active center of c-secretase
[4]. How c-secretase accomplishes the hydrolysis of peptide bonds
in the hydrophobic environment of the membrane is only partially
understood. TMDs 6 and 7 of PSEN around the catalytic
aspartate residues form a hydrophilic cavity within the membrane
that may allow access for water molecules required to hydrolyze
peptide bonds [5,6]. In addition, it appears that the substrate
initially binds to a distinct substrate-binding (docking) site on the
outer surface of the c-secretase complex and is subsequently
transported into the active site and cleaved [7].
Despite the limited knowledge of the catalytic mechanism of c-
secretase and the lack of high-resolution structural data, a large
number of small molecule c-secretase inhibitors (GSIs) with
excellent potency and in vivo properties have been developed [8].
Unfortunately, both preclinical and clinical studies have demon-
strated that inhibition of c-secretase is associated with prohibitive
side effects due to suppression of Notch processing and signaling
[8,9]. c-Secretase modulators (GSMs) are small molecules that
selectively lower generation of the highly amyloidogenic Ab42
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alternative to GSIs [10]. The first GSMs were described in the
class of non-steroidal anti-inflammatory drugs (NSAIDs) [11].
However, these NSAID-type GSMs suffered from low potency
and brain penetration. Recently, GSMs with nanomolar potency
and favorable pharmacological properties have been reported in
two major structural classes: carboxylic acids with structural
similarities to NSAIDs (acidic GSMs) and compounds based on
bridged aromatics that do not resemble NSAIDs and lack a
carboxylic acid group (non-acidic GSMs) [10].
Several studies have confirmed that GSMs modulate enzyme
activity in cell-free c-secretase assays [12,13,14]. However, aside
from this compelling evidence that GSMs directly interact with the
c-secretase complex, their molecular mechanism remains largely
undefined. Photo-affinity labeling studies have identified PSEN as
the molecular target of different classes of GSIs [7,15,16,17]. In
contrast, previous attempts to elucidate the molecular target of
GSMs have produced conflicting results and both the substrate
amyloid precursor protein (APP) and subunits of the c-secretase
complex have been proposed [18,19,20,21]. Using a novel photo-
probe based on a potent piperidine GSM, we have now
demonstrated that PSEN is the molecular target of acidic GSMs
in living cells.
Results
We recently presented the GSM BB25, derived from Merck
patent WO20006043064, which lowered Ab42 levels in cellular
assays with an IC50=87 nM and served as a starting point for the
synthesis of our GSM photo-probe AR243 [22] (Figure 1). In this
compound class, potent acidic GSMs such as GSM-1 with good
bioavailability, brain penetration and Ab42-lowering efficacy in
AD mouse models have been described [23,24,25]. Because of
inconsistent results in previous attempts to establish the GSM
target [18,19], we applied strict criteria to the design of the photo-
probe. These included potency in the nanomolar range, small size
to avoid steric hindrance, and incorporation of a diazirine photo-
reactive group to allow cross-linking in living cells. Structure
activity relationships that we obtained during the synthesis of
BB25 enabled us to synthesize the photo-probe AR80 matching
these criteria (Figure 1). The preserved GSM activity of AR80
(IC50=190 nM) confirmed the tolerance of the scaffold for the
introduction of the diazirine group on the para position of the
lower aromatic ring, providing a non-invasive probe due to near
complete similarity with the parent compound BB25. Subsequent-
ly, the biotin moiety for affinity purification was placed on the
alkynyl side chain, yielding the photo-probe AR243. Briefly,
compounds were synthesized via a copper-catalyzed three
component coupling reaction between a racemic piperidine 1,a
diazirinyl-benzaldehyde 2 and a terminal alkyne 3 (Figure 2A).
To establish the bioactivity of the photo-probe, CHO cells with
stable overexpression of wild type APP and PSEN1 were treated
with AR243 and Ab levels in culture supernatants were measured
by sandwich ELISA. This demonstrated that AR243 behaved like
a typical GSM and lowered Ab42 levels with an IC50=290 nM,
Figure 1. Chemical structures and Ab42-lowering activities of c-secretase modulators used in this study. IC50 values were determined
after treatment of CHO cells with stable co-expression of wild type human APP and PSEN1 as described in the Experimental Procedures. Note that
AR366 is an inverse c-secretase modulator with Ab42-raising activity.
doi:10.1371/journal.pone.0030484.g001
c-Secretase Modulators Target Presenilin
PLoS ONE | www.plosone.org 2 January 2012 | Volume 7 | Issue 1 | e30484comparable to the potency of the parent compound BB25
(Figure 2B).
To identify the molecular target of AR243, cellular membranes
were prepared from neuronal N2a-ANPP cells, which stably
overexpress APP and all four subunits of the c-secretase complex
[26], and solubilized in 0.25% CHAPSO. These conditions have
previously been shown to preserve the integrity and bioactivity of
the c-secretase complex [7,16]. Subsequently, membrane prepa-
rations were incubated with 0.5 mM of the photo-probe or DMSO
vehicle, UV irradiated, and putative target proteins were affinity
purified using streptavidin beads. The purified material was
resolved on SDS gels and probed by Western blotting with
antibodies against the four subunits of the c-secretase complex or
the substrate APP. Western blotting with the monoclonal antibody
PSN2 demonstrated that the GSM photo-probe AR243 bound the
N-terminal fragment of PSEN1 (PSEN1-NTF) (Figure 3). Omit-
ting the UV irradiation or incubation of membranes with a 20-fold
higher concentration of compound AR80 (IC50=190 nM), which
was structurally identical to the photo-probe but lacked the biotin
moiety, did not result in a Western blotting signal. As expected,
adding an excess of the parent compound BB25 (100 mM) during
incubation of membrane preparations with the photo-probe
efficiently reduced the labeling signal. Western blotting for the
C-terminal fragment of PSEN1 (PSEN1-CTF) and the remaining
c-secretase subunits APH-1, PEN-2 and Nicastrin did not
demonstrate binding by the photo-probe AR243. Likewise, neither
APP nor its membrane-bound C-terminal fragments (APP-CTFs),
which are generated after shedding of the APP ectodomain and
are the proximate c-secretase substrates, were labeled by the
photo-probe (Figure 3). Next, we sought to confirm binding of the
GSM photo-probe to endogenously expressed PSEN1-NTF. Since
the PSN2 antibody is specific for human PSEN1, we used
membrane preparations from human HEK293T cells and
performed the photo-affinity labeling as described above. Western
blotting demonstrated labeling of endogenous PSEN1-NFT but
not PSEN1-CTF by AR243 (Figure 4). Control experiments
including displacement of the photo-probe by an excess of parent
compound BB25 demonstrated specificity of the binding to
PSEN1-NTF.
Diazirine photo-reactive groups are activated by long-wave UV
light $300 nm, which permits the use of diazirine-based photo-
probes in living cells without the induction of acute cellular
toxicity. Hence, to provide critical confirmation for our in vitro
photo-labeling results, we treated N2a-ANPP cells with 0.2 mMo f
the photo-probe AR243 or DMSO vehicle and irradiated the live
cells with UV light (Figure 5A). Subsequently, cellular membranes
were prepared and target proteins of the photo-probe were
captured and analyzed as described for the cell-free experiments
above. Western blotting with PSN2 antibody demonstrated
efficient labeling of PSEN1-NTF, which was abolished by omitting
UV irradiation (Figure 5B). As expected, incubation of cells with
DMSO or a 100-fold higher concentration of compound AR80
lacking the biotin moiety did not result in a positive labeling signal.
In accordance with the labeling results in vitro, Western blotting did
not demonstrate binding of the photo-probe AR243 to PSEN1-
CTF in vivo (Figure 5B). None of the compound treatments nor the
UV irradiation caused cellular toxicity as monitored by alamar-
BlueH reagent (data not shown). However, because we observed
dose-dependent cytotoxicity with BB25 concentrations .10 mM,
we did not pursue competition experiments in living cells.
To investigate whether a binding site within the PSEN1-NTF is
unique to our photo-probe or likely common to potent second-
generation GSMs, we performed competition experiments with
other acidic and non-acidic GSMs in our cell-free system using
membranes from N2a-ANPP cells. JNJ-40418677, an acidic GSM
with considerable structural diversity to the photo-probe and an
IC50=290 nM, abolished binding of the photo-probe to PSEN1-
NTF (Figure 6A). In addition, three non-acidic GSMs with IC50
values below 100 nM competed binding of the photo-probe to
variable degrees. Whereas the non-acidic compound 1 reduced
binding of the photo-probe as effectively as the acidic compound
JNJ-40418677, compound 2 and E-2012 caused more modest
reductions (Figure 6B). Hence, in aggregate, the results of our
competition studies indicate that acidic and non-acidic GSMs
might share an overlapping binding site within the PSEN1-NTF.
Finally, earlier studies had demonstrated that derivatization of
acidic GSMs at the carboxylic acid group resulted in inverse
GSMs that increase Ab42 levels and concomitantly decrease the
production of shorter peptides such as Ab38 [27]. Accordingly,
through esterification we obtained the inverse GSM photo-probe
AR366, which increased Ab42 levels in our cellular assay with an
IC50=1.1 mM while dose-dependently lowering Ab38 levels.
Incubation of membranes from N2a-ANPP cells with 500 nM of
AR366 also resulted in photo-affinity labeling of PSEN1-NTF
suggesting that acidic GSMs and inverse GSMs either target the
same or a closely related binding site (Figure S1). In conclusion,
Figure 2. Synthesis and bioactivity of the c-secretase modulator photo-probe AR243. (A) The c-secretase modulator (GSM) photo-probe
AR243 was synthesized by a copper(I)-catalyzed three-component coupling between piperidine-derivative 1, diazirinyl-benzaldehyde 2, and biotin-
alkyne 3. The intermediate was then de-protected to yield the free acidic photo-probe. i: CuBr, molecular sieves, Tol. 60uC, 2 d. ii: TBAF, THF, r.t., 2 h.
(B) CHO cells with stable co-expression of wild type APP and wild type PSEN1 were treated with increasing concentrations of the photo-probe AR243
or DMSO vehicle, and Ab levels in conditioned media were quantified by sandwich immunoassay. AR243 caused a dose-dependent decrease in Ab42
levels with a concomitant increase in Ab38 levels, confirming its bioactivity as a potent GSM with an IC50 for Ab42 reduction of 290 nM.
doi:10.1371/journal.pone.0030484.g002
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prepared from neuronal N2a-ANPP cells, solubilized in 0.25% CHAPSO, and incubated with 0.5 mM of the photo-probe or DMSO vehicle. After UV
irradiation, putative target proteins were affinity purified using streptavidin beads as described in the Experimental Procedures. Western blotting of
the purified material demonstrated that the GSM photo-probe AR243 bound the N-terminal fragment of PSEN1 (PSEN1-NTF). Omitting the UV
irradiation or incubation of membranes with a 20-fold higher concentration of compound AR80, which lacked the biotin moiety, did not result in a
Western blotting signal. Adding an excess of the parent compound BB25 (100 mM) during incubation with the photo-probe efficiently reduced the
labeling signal. Western blotting did not demonstrate binding of the photo-probe AR243 to the C-terminal fragment of PSEN1 (PSEN1-CTF) or any of
the remaining c-secretase subunits APH-1, PEN-2 and Nicastrin. Likewise, neither full-length APP nor its membrane-bound C-terminal fragments (APP-
CTFs) were labeled by the photo-probe. The asterisk depicts an unspecific protein band of slower mobility that is present under all conditions.
Material that was bound non-specifically to the streptavidin beads is visible in the supernatant of the first washing steps but is completely removed
after the third wash. Input represents 0.02% (PSEN1-NTF) or 0.2% (all other proteins) of the total membrane material.
doi:10.1371/journal.pone.0030484.g003
Figure 4. The c-secretase modulator photo-probe AR243 targets endogenous PSEN1 in human HEK293T cells. Photo-affinity labeling
studies were performed with membrane preparations from human HEK293T cells as described in Fig. 1. Western blotting of purified target proteins
demonstrated labeling of endogenous PSEN1-NFT but not PSEN1-CTF by AR243. Co-incubation with an excess of parent compound BB25 (100 mM)
caused displacement of the photo-probe, demonstrating specificity of the binding to PSEN1-NTF. Input represents 0.02% of the total membrane
material.
doi:10.1371/journal.pone.0030484.g004
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GSMs using established cell-free conditions and living cells.
Discussion
Limiting Ab production and accumulation in the brain through
inhibition of c-secretase remains a rational approach for treatment
or prevention of AD. However, GSIs that function as classical
protease inhibitors and reduce enzymatic activity have displayed
mechanism-based toxicity, which appears to be largely attributable
to suppression of Notch processing [8]. In contrast, GSMs
selectively lower production of the amyloidogenic Ab42 peptides
and have been shown to spare processing of Notch [11,13].
While chemical development has yielded a second generation of
GSMs with nanomolar potencies and improved brain permeabil-
ity, the understanding of the molecular mechanism of GSMs is still
rudimentary [10]. Photo-affinity labeling and cross-competition
studies have demonstrated that, depending on their chemical
structure and mechanism of action, GSIs target either the active
site of c-secretase, the docking site or an allosteric site, which are
all located within the PSEN proteins [7,15,16,17]. Surprisingly,
previous photo-affinity labeling studies have suggested that the
binding site of NSAID-type GSMs resides within the substrate
APP and not within PSEN or one of the three other c-secretase
subunits [19]. In these studies, photo-probes based on the NSAID-
type GSM flurbiprofen and the inverse GSM fenofibrate with
benzophenone as a photo-reactive moiety were shown to bind
APP, either in the presence of purified recombinant APP-CTFs or
in crude membrane preparations of APP overexpressing cells.
However, the concept of GSMs targeting the substrate APP
contradicted important earlier observations, which suggested
interaction of GSMs with the enzyme complex and specifically
with PSEN. (i) Kinetic studies have demonstrated non-competitive
inhibition for NSAID-type GSMs in c-secretase in vitro assays
[12,13]. This indicated that the inhibitory effect of GSMs on Ab42
production could not be overcome by increasing substrate
concentrations, which would be expected for compounds with a
primary binding site within the substrate. (ii) While GSMs do not
impair the release of the intracellular signaling domain from
Notch-1, which is critical for Notch signaling, it has been
convincingly demonstrated that NSAID-type GSMs modulate c-
secretase cleavage events in the middle of the Notch-1 TMD [28].
These are analogous to the cleavage events in the APP TMD that
generate the Abpeptides suggesting that proteolytic processing of
at least APP and Notch is affected in a similar manner, thereby
questioning the specificity of GSMs for APP. (iii) The aspartyl
intramembrane-cleaving protease signal peptide peptidase (SPP)
has been demonstrated to harbor a binding site for NSAID-type
Figure 5. PSEN is the molecular target of the c-secretase modulator photo-probe AR243 in living cells. (A) Schematic illustration of the
photo-affinity labeling strategy in living cells. The active GSM photo-probe contains a diazirine photo-reactive group and a biotin moiety for affinity
purification. Live cells were treated with the photo-probe and subsequently irradiated in two steps at 365 and 302 nm. Note that the use of long-
wave UV light $300 nm did not induce acute cellular toxicity. Upon UV irradiation, the photo-probe forms a stable adduct with its specific target.
Cellular membranes were prepared and solubilized, and target proteins of the photo-probe were captured and affinity purified using streptavidin-
functionalized beads. After extensive washing, the purified material was eluted and resolved on SDS gels and probed by Western blotting. (B) N2a-
ANPP cells were incubated with 200 nM of AR243 or DMSO vehicle, and target proteins of the GSM photo-probe were purified as described above.
Western blotting with the antibody PSN2 demonstrated binding of the photo-probe to PSEN1-NTF. Incubation of cells with 20 mM of compound
AR80 that lacked the biotin moiety, or omission of UV irradiation did not result in a labeling signal. Consistent with the in vitro labeling results,
Western blotting with an antibody against the PSEN1-CTF did not demonstrate binding of the photo-probe confirming that the binding site is
located within the PSEN1-NTF.
doi:10.1371/journal.pone.0030484.g005
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homodimer without accessory proteins, and c-secretase and SPP
substrates do not show any overlap. This suggested that c-secretase
contains a binding site for GSMs that is conserved in SPP and,
accordingly, should be present in PSEN [29,30]. (iv) Circumstan-
tial evidence for the interaction of GSMs with the enzyme has
been provided by the observation that some FAD-associated
PSEN but not APP mutations render cells resistant to GSMs
[22,25,31,32].
Using a novel GSM photo-probe with nanomolar potency, we
have now identified the PSEN1-NTF as the molecular target of
acidic GSMs. In contrast, we did not observe binding of the photo-
probe to the substrate APP or any of the other c-secretase
subunits. Importantly, our GSM photo-probe with a diazirine
photo-reactive moiety allowed us to confirm targeting of the
PSEN1-NTF in living cells. A photo-probe with inverse Ab42-
raising activity similarly labeled PSEN1-NTF indicating that
acidic GSMs and inverse GSMs likely target similar or identical
binding sites. Under established cell-free conditions that preserve
the integrity of the c-secretase complex, binding of the photo-
probe to PSEN1-NTF was readily competed by unrelated acidic
and non-acidic GSMs indicating that our findings are not limited
to the specific class of piperidine GSMs. These findings are to
some extent consistent with a recent study by Kounnas et al. [18].
In this study, a potent non-acidic GSM was coupled to a solid
support and used for affinity chromatography. The affinity ligand
retained predominantly the c-secretase subunit PEN-2 and smaller
amounts of PSEN1-NTF and PSEN1-CTF from cellular lysates
[18]. However, this was only observed when cells were solubilized
in 1% Triton X-100 or b-D-maltoside, detergent conditions that
do not support c-secretase activity, whereas solubilization in
CHAPSO did not result in PEN-2 retention. Furthermore, it was
not investigated whether the affinity ligand preserved its GSM
activity after immobilization [18]. Notably, our results are entirely
consistent and complementary to a recent study by Ebke and
colleagues, who identified the PSEN1-NTF as the molecular target
of a distinct class of GSMs, non-acidic aminopyrimidines [21].
During preparation of this manuscript, we further learned that
Ohki and colleagues had identified the PSEN1-NTF as the target
of acidic, piperidine GSMs using a photo-probe that is similar but
structurally clearly distinct from our probe [33].
The reasons for the divergent results of photo-affinity labeling
studies with NSAID-type GSMs and the second-generation
piperidine GSMs are not known. However, given the low potency
of the parent compounds, the photo-probes based on NSAID-type
GSMs were applied at high concentrations (10–100 mM) in the
photo-affinity labeling studies, raising concerns for non-specific
interactions. Moreover, many GSMs share common structural
features with known aggregation inhibitors such as extended
conjugated aromatics and anionic moieties that are characteristic
of binders to hydrophobic patches. Indeed, some GSMs have been
reported as weak Ab aggregation inhibitors and, vice-versa, potent
aggregate binders such as X-34 and chrysamine G as moderate
GSMs [19]. Noteworthy, the benzophenone cross-linking moiety
used in the photo-affinity labeling studies with NSAID-type GSMs
also shows strong structural similarity with fenofibrate and, in
addition, with potent amyloid binders in the anthraquinone family
[34,35]. Hence, the cross-activities in c-secretase modulation and/
Figure 6. Structurally divergent acidic and non-acidic c-secretase modulators compete binding of the photo-probe AR243 to the N-
terminal fragment of PSEN1. Competition experiments were performed under cell-free conditions with membrane preparations from N2a-ANPP
cells. Membranes were co-incubated with 0.5 mM of the photo-probe AR243 and 100 mM of acidic or non-acidic GSM competitor compounds. (A) The
acidic GSM JNJ-40418677 abolished binding of the photo-probe to PSEN1-NTF. (B) Three non-acidic GSMs competed binding of the photo-probe to
variable degrees. Compound 1 reduced binding of the photo-probe as effectively as the acidic compound JNJ-40418677. Compound 2 and E-2012
only partially competed binding of the photo-probe to PSEN1-NTF. Input represents 0.02% of the total membrane material.
doi:10.1371/journal.pone.0030484.g006
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putative targets and are not mutually exclusive in view of the
available data [36,37]. Clearly, we cannot exclude the possibility
that NSAID-type GSMs target a different binding site than
piperidine-based GSMs. Ebke et al have performed competition
studies with the NSAID GSM sulindac sulfide and observed
strongly reduced binding of their non-acidic GSM photo-probe
indicative of overlapping binding sites [21]. Competition exper-
iments are generally not able to distinguish between direct and
allosteric competition for a specific binding site. Therefore, it
remains possible that sulindac sulfide has a specific binding site
within the substrate APP and reduces binding of the photo-probe
to PSEN through allosteric interaction. However, because of the
superior properties of the photo-probes based on second-
generation GSMs, the overall structural similarities between
NSAID GSMs and second generation acidic GSMs, the prior
evidence from cell biological studies indicating a binding site of
NSAID GSMs within PSEN, and the new evidence from
competition experiments, the modulatory activity of GSMs
appears to be strongly linked to interaction with PSEN. Future
studies aided by tandem mass spectrometry might allow to fully
define the binding sequence of GSM photo-probes [38]. In
addition, fluorophore-coupled photo-probes that can be cross-
linked in live cells might be useful to investigate whether GSMs
target specific subcellular pools of c-secretase. Such studies could
achieve additional insights into the molecular mechanism of GSMs
and Ab42 generation, and might provide a basis for rational
chemical design of GSMs.
Materials and Methods
Chemistry and Compounds
Compounds 1, 2, E-2012 and BB25 have been described
previously [22]. Compound JNJ-40418677 was synthesized
according to procedures described in WO2006112552 [39]. The
chemical procedures for the GSM photo-probes used in this study
are described here in exemplary fashion for compound AR243 (2-
(1-(7-((5-((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)-
pentanoyl)oxy)-1-(4-(3(trifluoromethyl)-3H-diazirin-3-yl)phenyl)hept-2-yn-
1-yl)-2-(4(trifluoromethyl)phenyl)piperidin-4-yl)acetic acid). The experi-
mental procedures and characterization data for compounds
BB25, AR80 and AR366 will be reported elsewhere.
All reactions were performed under an inert atmosphere of
Argon, unless otherwise stated.
1H-NMR and
13C-NMR data
were obtained on a Bruker Avance DPX 400 or DPX 500. Spectra
were recorded at 298 K and the chemical shifts are expressed in
ppm relative to solvent signals (
1H-NMR: MeOD 3.31;
13C-NMR:
MeOD 49.00). Preparative HPLC was performed on a Shimadzu
LC-8A system using a gradient-system (H2O, 0,1% TFA and
acetonitrile) at 5 ml/min on a 10x250 mm Supelco Ascentis C18
column. HRMS-spectra were recorded on a MAT 95 XL or MAT
90 mass spectrometer from Thermo Finnigan. All reagents were
obtained from Sigma-Aldrich (Munich, Germany), Alfa-Aesar
(Ward Hill, USA), Acros Organics (Geel, Belgium) or Fluorochem
(Hadfield, UK) and used as received. In a glovebox under inert
atmosphere were successively introduced in a pressure-tight vial:
120 mg of 4-(3-(trifluoromethyl)-3H-diazirin-3-yl)benzaldehyde
(0,56 mmol), 2-(trimethylsilyl)ethyl 2-(2-(4-(trifluoromethyl)phe-
nyl)piperidin-4-yl)acetate (326 mg, 0,84 mmol) and Hex-5-yn-1-
yl 5-((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-
yl)pentanoate (273 mg, 0,84 mmol), together with activated mol-
sieves (,1 g / 10 ml solvent) and Copper(I)bromide (241 mg,
1,68 mmol). Toluene (6,3 ml) was added and the reaction was
heated to 60uC for 2 days. The dark green suspension was filtered
twice through celite, evaporated and filtered through a pad of
silica-gel using DCM/MeOH 95/5. After evaporation, the
obtained crude oil was dissolved in THF (15 ml) and TBAF
(1 M in THF) (1,12 ml, 1,12 mmol) was slowly added at r.t. The
reaction was allowed to proceed for 2 h before being diluted with
EtOAc and water. The pH of the water layer was set neutral and
washed with EtOAc. The organic layers were combined, washed
with brine, dried over MgSO4, filtered and evaporated. The
obtained crude oil was purified on prep-HPLC to afford AR243 as
a white foam (42 mg, 9,3%).
1H-NMR (400 MHz, MeOD) d=1.39–1.91 (m, 12H), 1.99 (m,
1H), 2.12 (m, 1H), 2.21 (m, 1H), 2.31 (d, J=6.8 Hz, 2H), 2.36 (t,
J=7.4 Hz, 2H), 2.55 (td, J1 =6.8 Hz, J2= 2.1 Hz, 2H), 2.68 (d,
J=12.9 Hz, 1H), 2.89 (dd, J1=12.9 Hz, J2=4.9 Hz, 1H), 2.98
(m, 1H), 3.10–3.20 (m, 2H), 4.19 (t, J=6.5 Hz), 4.28 (dd, J1=8.1,
J2=4.5 Hz, 1H), 4.38–4.50 (m, 2H), 4.90 (s, 1H), 7.32 (d,
J=8.1 Hz, 2H), 7.61 (d, J=8.1 Hz, 2H), 7.76–7.89 (m, 4H).
13C-NMR (100 MHz, MeOD) d=19.14, 25.98, 25.99, 29.17,
29.47, 48.31, 29.71, 30.58, 33.31, 34.84, 40.30, 40.71, 41.02,
56.97, 59.34, 61.62, 63.39, 65.03, 68.43, 71.58. 94.82, 123.45 (q,
J=275.2 Hz), 125.39 (q, J=275.5 Hz), 127.64 (q, J=3.3 Hz),
127.95, 129.92 (broad), 131.43, 131.59, 132.49 (q, J=32.5 Hz),
136.60, 143.46, 166.09, 175.40, 175.52 (diazirine-carbon not
resolved).
HRMS (ESI-TOF) for C39H43F6N5O5SH
+ (M+H) 808.2962,
found 808.2938.
Antibodies and cell lines
Monoclonal antibody IC16 raised against residues 1–15 of the
human Ab sequence, HRP-coupled carboxyl terminus-specific Ab
antibodies BAP24, BAP15 and BAP29 specific for Ab40, Ab42,
and Ab38, and polyclonal antibody CT15 against the last 15 C-
terminal amino acids of human APP have been described
previously [22,40]. Monoclonal antibody PSN2 against a synthetic
peptide corresponding to amino acids 31–56 of human PSEN1
was kindly provided by Dr. Hiroshi Mori [41]. The following
commercial antibodies were used: polyclonal antibody against the
C-terminal fragment of PSEN1 (Cat. No. 3622, Cell Signaling,
Danvers, USA), polyclonal antibody against PEN-2 (Cat.
No. 5451, Cell Signaling) and the C-terminal region of APH-
1aL (Cat. No. PRB-550P, Covance, Princeton, USA), polyclonal
antibody against the C-terminus of nicastrin (Cat. No. N1660,
Sigma-Aldrich). HRP-coupled secondary antibodies against mouse
or rabbit IgGs were purchased from Jackson ImmunoResearch
Europe Ltd. (Suffolk, UK). CHO cells with stable co-expression of
wild type human APP751 and human PSEN1 (PS70 cells), and
N2a cells stably transfected with human APP harboring the
‘‘Swedish’’ mutation and human PSEN1, Nicastrin, APH-1a and
PEN-2 (N2a-ANPP cells) have been described [26,31]. HEK293T
cells were purchased from GenHunter (Nashville, USA). All cell
lines were maintained in Dulbecco’s modified Eagle’s medium
with 10% fetal bovine serum, 1mM sodium pyruvate and 100
units/ml penicillin/streptomycin (Invitrogen).
Dose-response experiments, IC50 determinations, and
cytotoxicity assays
To determine IC50 values for the Ab42-lowering activity of
GSMs used in this study, PS70 cells were cultured in serum-
containing medium and treated for 24 h with 8 increasing
concentrations of each GSM or DMSO vehicle in triplicates.
Ab40, Ab42 and Ab38 peptide levels in conditioned cell culture
supernatants were measured in a previously described sandwich
ELISA assay [40]. For calculation of IC50 values, a non-linear
curve-fit with variable slope model was applied to the results.
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Cell viability was assessed using the alamarBlue
H reagent
(Invitrogen). N2a-ANPP cells were seeded at low density in 96-well
plates (4000 cells/well) and cultured for 24 h. The cells were then
treated in duplicates with increasing concentrations of the respective
compounds or DMSO as vehicle for an additional 24 h. 20 ml
alamarBlue
H was added to cells cultured in 200 mlm e d i u ma n d
incubated overnight. Absorbance was measured with a Paradigm
TM
microplate reader at 570 nm, using 600 nm as the reference
wavelength, and percent viability of vehicle control was calculated.
Photo-crosslinking and competition experiments
For photo-affinity labeling in living cells, N2a-ANPP were
treated overnight with 0.2 mM of the GSM photo-probe AR243.
Subsequently, cells were UV-irradiated on ice for 30 min at
365 nm and for 30 min at 302 nm. As negative controls, UV
irradiation was omitted or cells were incubated with DMSO
vehicle or compound AR80, which was structurally identical to
AR243 but lacked the biotin moiety. Cells were washed and
harvested in PBS and incubated with hypotonic buffer (10 mM
Tris pH 7.4, 1x protease inhibitor mix) for 10 min on ice. To
prepare cellular membranes, cells were passed 10 times through a
30G needle and centrifuged at 8006g, 10 min, 4uC. The post-
nuclear supernatant was centrifuged at 18.0006g, 45 min, 4uC.
The resulting membrane pellet was washed once with MES buffer
(50 mM MES, 150 mM NaCl, 5 mM MgCl2, 5 mM CaCl2,
pH 6.0), centrifuged at 18.0006g, 45 min, 4uC, and again
dissolved in MES buffer. The total protein concentration of the
membrane preparations was determined by BCA assay, concen-
trations and volumes of each sample were adjusted, and 5x RIPA
buffer was added to a final concentration of 1x RIPA buffer
(150 mM NaCl, 1.0% NP-40, 0.5% sodium deoxycholate, 0.1%
SDS, 250 mM Tris HCl, pH 8.0). Solubilization was allowed to
continue for 45 min at 4uC with gentle shaking. Insoluble debris
was pelleted by centrifugation at 18.0006g, 45 min, 4uC. Protein
concentrations were again determined and adjusted to equal levels
prior to the addition of streptavidin magnetic beads (Invitrogen).
Samples were incubated overnight at 4uC with gentle shaking, and
the streptavidin beads were washed 3 times for 30 min with 1x
RIPA buffer. Bound material was eluted with Laemmli buffer and
incubation at 65uC for 10 min with intermittent vortexing. The
eluted material was separated on 12% Bis-Tris gels and analyzed
by Western blotting. Chemiluminescence was recorded with a
LAS 3000 ECL camera system (Fuji Photo Film GmbH,
Duesseldorf, Germany) or on CL-XPosure film (Fisher Scientific
GmbH, Schwerte, Germany).
For photo-affinity labeling in vitro, membranes were prepared
from N2a-ANPP or HEK293T cells as described above. Prior to
the addition of compounds, membrane preparations were
incubated with streptavidin magnetic beads to deplete endoge-
nously biotinylated proteins. Membranes were then incubated
with 0.5 mM of the GSM photo-probe AR243 or DMSO vehicle
for 1 h at 4uC with gentle shaking. In competition experiments,
the photo-probe was co-incubated with 100 mM of acidic or non-
acidic GSM competitor compounds. 1% CHAPSO was used for
solubilization. Samples were diluted to contain 0.25% CHAPSO
and UV-irradiated. After the photo-crosslinking, to ensure
exposure of the bound biotin-tagged GSM, 1x RIPA buffer was
added to unfold/denature proteins. The pull-down and analysis of
labeled target proteins using streptavidin magnetic beads was
performed as described above.
Supporting Information
Figure S1 The photo-probe AR366 inversely modulates
c-secretase and targets the N-terminal fragment of
PSEN1. (A) Chemical structure of AR366, an inverse GSM
photo-probe. AR366 was obtained through esterification of the
carboxylic acid group in AR243. Note that, in contrast to AR243,
the biotin moiety for affinity purification was placed on the alkynyl
side chain via an amide bond. AR366 increased Ab42 levels with
an IC50=1.1 mM. (B) Incubation of solubilized membranes from
N2a-ANPP cells with 500 nM of AR366 resulted in photo-affinity
labeling of PSEN1-NTF suggesting that acidic GSMs and inverse
GSMs either target the same or a closely related binding site. Input
represents 0.02% of the total membrane material.
(TIF)
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